What is AMGEN INC listed on the DOW JONES?
Amgen Inc. is a biotechnology company listed on the Dow Jones Industrial Average, a benchmark index for stock markets. Representing a significant portion of the healthcare industry, Amgen is a top 30 Dow Jones company. Recently, Amgen's stock saw a notable drop of 7.14% on the NASDAQ, weighing heavily on the overall index. This decline was amplified following the publication of the results of its experimental drug MariTide, which impacted its stock performance. With a weight of 4.84% in the index, Amgen is one of the main companies whose evolution strongly influences the Dow Jones.
\n\n\n\nIN BRIEF | \n
| L'action biotechnology Amgen Inc (NASDAQ:AMGN) suffered a fall of 7.14%, strongly influencing the index Dow Jones. | \n
| Amgen is a key player in the sector of health, with a weight of 4.84% in the composition of the Dow Jones in 2024. | \n
| Despite its sharp decline, Amgen remains an important value among the leading stocks listed on the NASDAQ or at NYSE. | \n
| The recent publication of the results of their experimental drug MariTide generated a marked drop in their action on the S&P 500. | \n
| Several investment funds and UCITS hold a significant position in Amgen Inc. | \n
| The performance of Amgen plays a role in the evolution of the index Dow Jones, a crucial stock index measuring 30 major U.S. companies. | \n
AMGEN INC, a leader in the biotechnology, is among the flagship companies listed in the American index Dow Jones Industrial Average. Although inclusion in this prestigious index is seen as a sign of stature and stability, the company has recently gone through a tumultuous period in the stock market.
\n\n\nRecent developments
\n\n\nTHE November 13, 2024, AMGEN Inc stock experienced a severe drop of 7.14%, significantly influencing the overall movement of the Dow Jones. This decline was exacerbated by the disappointing results of their experimental drug, MariTide, resulting in a loss of more than 11.03 points in the S&P 500, bringing the stock price to $261.58.
\n\n\nImplications for the Dow Jones
\n\n\nThe sharp drop in AMGEN Inc did not remain without consequences on the Dow Jones. With a weight of 4.68% in the index, the fall slowed the progress of this historic index, which represents 30 of the most influential companies listed on the New York Stock Exchange (NYSE) and NASDAQ. The volatility of its components, such as AMGEN, shows that even industrial giants are under pressure from internal and external developments.
\n\n\nOutlook analysis
\n\n\nDespite recent setbacks, AMGEN Inc still holds a strategic position within the Dow Jones and healthcare industry. According to Jean-Marc Dubois, financial analyst at ABC Advisors, “AMGEN has a strong portfolio of approved products and expert management, which should allow the company to rebound in the medium term. » AMGEN's long-term outlook remains promising considering ongoing advances in biotechnology.
\n\n\nHow AMGEN manages its biotechnology developments, including clinical testing and regulatory approvals, will be crucial to its future performance. Furthermore, their evolution will also influence the performance of the index. US 30, nicknamed the Dow Jones, and vice versa.
\n\n\n
\nAMGEN INC: Chronological Journey of the Biotech Company on the Dow Jones
\n\n\nAMGEN INC, a major player in the biotechnology industry, has established itself today as one of the key companies in the health sector, listed on both the NASDAQ and the prestigious Dow Jones Industrial Average. Founded in 1980 in California, Amgen has, over the years, developed notable expertise in the research, development and marketing of innovative medicines intended to address unmet medical needs.
\n\n\nIn 2024, Amgen appears with a significant weight of 4.84% in the composition of the Dow Jones, which testifies to its influence and stature on the market. However, despite this enviable position, the company has experienced turbulent times, as evidenced by the recent drop in its stock on November 13, 2024. On that day, Amgen stock plunged more than 7%, marking one of the largest declines in the S&P 500, and largely contributing to the decline in the Dow Jones.
\n\n\nThe sudden and sharp drop in the stock price to $261.58 was driven by disappointing results from its experimental drug, MariTide. The announcement heightened investor concerns, highlighting the challenges Amgen faces in a highly competitive industry.
\n\n\nIt should be noted that the structure of Dow Jones differentiates itself from other indices by its weighting based on stock price, rather than market capitalization. This means that a significant movement in the share price of a company like Amgen, with its 4.68% weight in the index, can have a disproportionate influence on the overall movement of the Dow Jones.
\n\n\nDespite these challenges, Amgen continues to attract the attention of investment funds, mutual funds, trackers and SICAVs, which hold significant open positions in its shares. This sustained confidence from institutional investors is proof of the solidity of its fundamentals and its long-term potential.
\n\n\nToday, Amgen Inc. remains a leading company in the global biotechnology arena, continually engaged in a quest for innovation and improvement in medical treatments, thereby consolidating its strategic place within the Dow Jones and in international financial markets.
\n\n\n\nAMGEN INC company within the Dow Jones
\n\n\n| Features | \nDetails | \n
| Index Included | \nDow Jones | \n
| Founder | \nGeorge B. Rathmann | \n
| Sector | \nHealth | \n
| Weighting in the Dow Jones (2024) | \n4.84% | \n
| Performance Recent | \nFall of 7.14% | \n
| Lowest Stock in the S&P500 | \n11.03% to 261.58 USD | \n
| Presence on the Nasdaq | \nYes | \n
| Users | \nInvestors and UCITS | \n
| Stock Price (Recent) | \n$267.3 | \n
AMGEN INC company listed on the DOW JONES: what is it?
\n\n\nAMGEN INC is a renowned biotechnology company listed among the companies listed on the Dow Jones Industrial Average. This healthcare giant contributes to the stock index alongside just 29 other leading companies in the United States. Its inclusion in this very selective index demonstrates its financial strength and its influence on the global market.
\n\n\nAMGEN INC's flagship products
\n\n\nAMGEN is recognized for its innovations in the field of biotechnology, particularly through the development and commercialization of pharmaceutical products. Among its best-selling products, Enbrel, a drug intended for the treatment of rheumatoid arthritis, is positioned as a real bestseller. THE Prolia, used to treat osteoporosis, is also a flagship product that generates significant sales.
\n\n\nIn terms of numbers, Enbrel has generated billions of dollars in annual revenue for AMGEN, showing its dominance in the arthritis treatment market. Likewise, Prolia continues to climb the sales rankings, contributing significantly to the company's financial performance.
\n\n\nThe business failures of AMGEN INC
\n\n\nDespite its resounding successes, AMGEN is no stranger to business challenges. One of the notable failures has to do with its experimental drug MariTide. After the release of unconvincing test results, AMGEN shares fell sharply by more than 7% to $261.58, impacting its reputation and sales prospects.
\n\n\nThese setbacks highlight the risks inherent in the biotechnology sector, where innovation and clinical trial results can tip a company between dazzling success and crushing failure.
\n\n\n\n| Majority Shareholders | \nParticipation Rate | \n
| Vanguard Group | \n10% | \n
| BlackRock Inc | \n9% | \n
| State Street Corporation | \n7% | \n
| Fidelity Management & Research | \n5% | \n
AMGEN INC is a company specializing in the sector of health. It is listed on NASDAQ and is part of the stock market index Dow Jones, which includes 30 major American companies. This index is used to measure the performance of the American stock market. AMGEN INC has a weight of 4.68% in this index.
\n\n\n\n| Year | \nDividend per Share (in USD) | \nChange in Dividend (%) | \n
|---|---|---|
| 2019 | \n5.80 | \n- | \n
| 2020 | \n6.40 | \n+10.35% | \n
| 2021 | \n7.04 | \n+10.00% | \n
| 2022 | \n7.76 | \n+10.23% | \n
| 2023 | \n8.40 | \n+8.25% | \n
Amgen Inc. is a biotechnology company listed on the index Dow Jones, one of the most famous stock indices which represents 30 main stocks listed on the NASDAQ or the New York Stock Exchange (NYSE). Amgen's dividend history shows an increasing trend over the years, illustrating its ability to generate stable cash flow.
\n\n\n\nPerformance and Analysis of Amgen Inc Shares within the Dow Jones
\n\n\nThe action of biotechnology Amgen Inc, listed on the NASDAQ under the symbol AMGN, recently experienced a notable decline after announcing disappointing results for its experimental drug MariTide. In fact, the stock fell by 7.14% during a turbulent day, thus impacting the entire Dow Jones, an iconic stock index of the New York Stock Exchange.
\n\n\nAmgen, which is part of Dow Jones Industrial Average, represents a significant part of the health sector with a weight of 4.84%. This decline therefore contributed to a decline in the index, which is based on the nominal price of the shares of the companies included in it rather than on their market capitalization.
\n\n\nTHE Dow Jones itself is a key barometer of U.S. economic performance, measuring the performance of 30 major companies. Among these, Amgen is a leading biotechnology company, alongside other giants like Visa Inc. and Caterpillar Inc.
\n\n\nThe fluctuation in the Amgen share price, which was recorded during this day with a drop to $261.58, makes it one of the most notable declines in the S&P 500, another benchmark stock index in the United States. Several investment funds, mutual funds, and other financial products have a significant open position in Amgen Inc., which draws investors' attention to the stock's current volatility.
\n\n\nFAQ about AMGEN INC listed on the DOW JONES
\n\n\nQ: What is AMGEN INC?
\n\n\nA: AMGEN INC is a company in the biotechnology sector, known for being listed on the NASDAQ under the symbol AMGN.
\n\n\nQ: What is AMGEN's role in the Dow Jones?
\n\n\nA: AMGEN INC is one of the companies listed in the Dow Jones, an index representative of the performance of large companies in the United States.
\n\n\nQ: How important is AMGEN within the Dow Jones in terms of weighting?
\n\n\nA: AMGEN holds significant weight within the Dow Jones with a weighting of approximately 4.68%.
\n\n\nQ: Why has AMGEN stock fallen recently?
\n\n\nA: AMGEN INC stock saw a significant decline of more than 7%, thus influencing the decline of the Dow Jones.
\n\n\nQ: What was the impact of the publication of the results of the experimental drug MariTide?
\n\n\nA: The results contributed to a drop in 11.03% of AMGEN stock in the S&P500, at $261.58.
\n\n\nQ: How is the Dow Jones weighted?
\n\n\nA: The composition of the Dow is weighted by nominal stock price rather than market capitalization or enterprise value.
\n\n
